Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Spotlight: Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals And What’s Next

Executive Summary

Atorvastatin launch “reinforced the belief in the Indian generic companies,” Sawhney says. Approval of anti-malarial Synriam, the first novel drug developed in India, will lead to “belief that we from India can also develop new products.”

You may also be interested in...



Lipitor Goes Generic, But First-Filer Ranbaxy’s Approval Leaves Plenty Of Questions In Its Wake

Ranbaxy launches generic atorvastatin despite not having reached a final settlement with FDA on GMP violations and data integrity issues. Teva’s role in Ranbaxy’s approval and launch is unclear, although the company will get a cut of the first-filer’s profits during the 180-day exclusivity period.

Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.

TOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy

U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant

MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel